Ichnos Glenmark Innovation (IGI) Announces Global Commercialization Strategy for ISB 2001 Following Licensing Deal with AbbVie

Glenmark to develop, manufacture and lead commercialization in Emerging Markets;
AbbVie to lead global development and manufacturing and commercialize in North
America, Europe, Japan, and Greater China
New York and Mumbai, July 10, 2025: Ichnos Glenmark Innovation, Inc. (IGI), a global, fully
integrated clinical-stage biotechnology company focused on developing multispecificsTM in
oncology, today announced its global commercialization strategy for its lead investigational
asset, ISB 2001developed using IGI’s proprietary BEAT® protein platform, for oncology and
autoimmune diseases. This follows the execution of an exclusive licensing agreement with
AbbVie (NYSE: ABBV).
Under the terms of agreement, IGI partners with AbbVie and grants exclusive rights to globally
develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and
Greater China while Glenmark Pharmaceuticals will develop, manufacture and lead
commercialization of ISB 2001 across Emerging Markets including the rest of Asia, Latin America,
the Russia/CIS region, the Middle East, Africa, Australia, New Zealand and South Korea.
“Our collaboration with AbbVie and Glenmark reflects IGI’s mission to accelerate access to
transformative multispecificsTM for patients worldwide,” said Cyril Konto, M.D., President,
Executive Director and CEO of IGI. “AbbVie’s reach in major markets combined with Glenmark’s
commercial strength in Emerging Markets, creates complementary access pathways for
ISB 2001, a trispecific T-cell engager with promising potential in Multiple Myeloma.”
“At Glenmark, we are committed to expanding access to innovative cancer treatments across
Emerging Markets where unmet need and growth potential intersect,” said Christoph Stoller,
President – Europe and Emerging Markets, Glenmark Pharmaceuticals. “The addition of ISB 2001
is a natural evolution of our oncology strategy. With our deep commercial footprint, strong
regulatory capabilities, and experience in launching breakthrough assets like BRUKINSA® and
TEVIMBRA® in India, and rights to commercialize QiNHAYO® (envafolimab), a PD-L1 checkpoint
inhibitor, in Emerging Markets, we are well positioned to deliver impactful treatment option for
patients with difficult-to-treat cancers through ISB 2001.”
This strategic collaboration marks a defining milestone in IGI’s scientific journey, accelerating
ISB 2001’s path to patients and sharpening the focus on advancing the next generation of
BEAT®-enabled assets in oncology